Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain
NCT ID: NCT01089855
Last Updated: 2017-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
123 participants
INTERVENTIONAL
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Mirogabalin for Central Neuropathic Pain
NCT03901352
Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy
NCT00496457
A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
NCT01056315
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
NCT00548925
An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics
NCT00870454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carbamazepine
Carbamazepine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carbamazepine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female aged from 21 to 65 years
* Informed consent
* HbA1C \< 11%
Exclusion Criteria
* Prior hospitalization for severe hypoglycemia
* Pregnancy
* Hepatitis
* Diabetes foot
* AVB (auriculo-ventricular conduction disturbance)
* Patient treated by antidepressant drugs
* Patient treated with other antiepileptic drug
* Patients with blood ion disturbance
* Patient with neutropenia
* Glaucoma
* Bladder Adenoma
* Alcohol abuse
* Creatinin clearance \< 60 ml/ minute
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Novartis Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigational Site
Rabat, , Morocco
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTEG111ZMA01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.